Targets › TNFRSF4
8 programs from 8 companies in 9 trials: 6 Phase 1, 3 Phase 2; Oncology; next expected readout Nov 2026.
Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity..; FUNCTION: (Microbial infection) Acts as a receptor for human herpesvirus 6B/HHV-6B. (UniProt, P43489)
Open in Phaseline: the race on TNFRSF4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Southern California | Anti-OX40 Antibody PF-04518600 OX40 (TNFRSF4) agonist antibody | TNFRSF4 | Phase 2 | Clear Cell Renal Cell Carcinoma | Dec 2026 |
| Providence Health & Services | INBRX-106 OX40 agonist antibody | TNFRSF4 | Phase 2 | Triple Negative Breast Cancer | Jun 2027 |
| Inhibrx Biosciences | INBRX-106 OX40 receptor agonist antibody | TNFRSF4 | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC); Solid Tumor | Dec 2029 |
| Regeneron Pharmaceuticals | REGN7075 OX40 (TNFRSF4) agonist antibody | TNFRSF4 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
| Ruijin Hospital | CS01 Agonistic anti-OX40 monoclonal antibody | TNFRSF4 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Dec 2026 |
| GSK | Gsk-3174998 (GSK3174998) Tumor necrosis factor receptor superfamily member 4 agonist | TNFRSF4 | Phase 1 | Multiple Myeloma | Mar 2027 |
| M.D. Anderson Cancer Center | Ivuxolimab OX40 agonist monoclonal antibody | TNFRSF4 | Phase 1 | Advanced Malignant Solid Neoplasm | Apr 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | CAR-T cells secreting scFv against OX40 CAR-T cell therapy with engineered OX40 co-stimulation | TNFRSF4 | Phase 1 | Lung Cancer | Jun 2029 |
Head and Neck Squamous Cell Carcinoma (HNSCC) (1) Solid Tumor (1) Advanced Solid Tumors (1) Multiple Myeloma (1) Locally Advanced or Metastatic Solid Tumors (1) Triple Negative Breast Cancer (1) Clear Cell Renal Cell Carcinoma (1) Advanced Malignant Solid Neoplasm (1) Lung Cancer (1)
mixed (5), antibody (2)
Inhibrx Biosciences (1) Regeneron Pharmaceuticals (1) GSK (1) Ruijin Hospital (1) Providence Health & Services (1) University of Southern California (1) M.D. Anderson Cancer Center (1) Second Affiliated Hospital of Guangzhou Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.